Spots Global Cancer Trial Database for An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Official Title: Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155

Study ID: NCT00818480

Conditions

Prostate Cancer

Melanoma

Non-Hodgkin's Lymphoma

Interventions

YM155

Study Description

Brief Summary: This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.

Detailed Description: The main objective of the study is to continue to evaluate the safety and efficacy of YM155. Each subject will be treated at the dose he/she was receiving at the completion of his/her previous phase I or phase II YM155 study.